MedTrace Logo

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

NCT06862739 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2026-04-17

No results posted yet for this study

Summary

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Conditions

Interventions

COMBINATION_PRODUCT

Empagliflozin+Linagliptin+Metformin

Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients

Sponsors & Collaborators

  • Nabiqasim Industries (Pvt) Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2026-04-30
Completion
2026-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06862739 on ClinicalTrials.gov